Selective Estrogen Receptor Modulators (SERM)

Subscribe to Selected New Research on Selective Estrogen Receptor Modulators

736 relevant articles (68 outcomes, 119 trials/studies) found for this Bio-Agent

Description: A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63)

Also Known As:

SERM; Selective Estrogen Receptor Modulator; SERMs; Estrogen Receptor Modulator, Selective; Estrogen Receptor Modulators, Selective

Relationship Network

Bio-Agent Context: Research Results

Hormones, Hormone Substitutes, and Hormone Antagonists

Hormone Antagonists: 26

Estrogen Receptor Modulators: 1737

Selective Estrogen Receptor Modulators: 736

Chemical Actions and Uses

Pharmacologic Actions: 50

Physiological Effects of Drugs: 1

Hormones, Hormone Substitutes, and Hormone Antagonists

Hormone Antagonists: 26

Estrogen Receptor Modulators: 1737

Selective Estrogen Receptor Modulators: 736

Experts

1.	Jordan, V Craig: 5 articles (12/2007 - 02/2002)
2.	Sporn, Michael B: 4 articles (10/2006 - 10/2002)
3.	Gennari, Luigi: 3 articles (01/2007 - 06/2006)
4.	Labrie, Fernand: 3 articles (10/2006 - 10/2003)
5.	Risingsong, Renee: 3 articles (10/2006 - 10/2002)
6.	Suh, Nanjoo: 3 articles (10/2006 - 10/2002)
7.	Williams, Charlotte R: 3 articles (10/2006 - 10/2002)
8.	Ganz, Patricia A: 2 articles (07/2008 - 08/2004)
9.	Powles, Trevor J: 2 articles (01/2008 - 01/2006)
10.	Martini, Giuseppe: 2 articles (01/2007 - 09/2006)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 10/01/2002 - "This metabolic monitoring can thus serve to evaluate the efficacy of new selective estrogen receptor modulators and may be further extended to improve diagnosis and prognosis of breast cancer." 11/01/2006 - "Recent results from clinical trials using SERMs to reduce the risk of breast cancer." 09/01/2005 - "RESULTS: This in vitro study clearly demonstrates differences in results if various HT preparations, combined with SERMs, are added to ER + and ER- breast cancer cell lines" 01/01/2004 - "The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials." 12/01/2001 - "The use of selective oestrogen receptor modulators (SERMs) and other hormonal therapies for the treatment of breast cancer is common, yet few studies have examined the possible cognitive effects of this form of treatment" Order ALL the reference details at left...
2.	Osteoporosis 10/01/2008 - "New generation of anti-resorptive agents (anti-RANKL antibody and a new SERM, bazedoxifene) are promising and will be soon available for the treatment of osteoporosis" 08/01/2007 - "Many SERMs are in development for prevention and treatment of osteoporosis" 09/01/2006 - "Keeping these results in mind, it is our responsibility to critically evaluate and decide timing and length of treatment, as well as subjects with benefits or risks for the treatment of osteoporosis by SERMs." 05/01/2006 - "SERMs for treatment of osteoporosis: state-of-the-art and perspectives]" 01/01/2006 - "Answering to these questions will have great impact in getting the decision of possible SERMs usage in the treatment of osteoporosis in elderly males." Order ALL the reference details at left...
3.	Postmenopausal Osteoporosis 01/01/2007 - "Animal studies and early clinical studies suggest effects in the bone similar to other SERMs with prevention of postmenopausal bone loss" 05/01/2007 - "Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis." 01/01/2007 - "Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development." 09/01/1999 - "The role of SERMs in the management of postmenopausal osteoporosis." 06/19/1999 - "SERMs could offer new therapeutic opportunities for the prevention of post-menopausal osteoporosis." Order ALL the reference details at left...
4.	Neoplasms (Cancer) 01/01/2008 - "It is clear from three randomised trials that SERMs prevent ERalpha+ tumors only in women at increased risk and at population risk of BC entered into these trials" 06/01/2007 - "In all studies, average tumor volumes in SERM-treated animals declined over the course of treatment" 10/01/2006 - "For the treatment studies, mice with tumors were fed combinations of a SERM and 268 for 4 weeks" 02/01/2008 - "However, only a proportion of ER-positive tumors respond to SERMs, and resistance to hormonal therapies is still a major problem" 01/01/2008 - "The breast and endometrial tumor cells selectively become SERM stimulated" Order ALL the reference details at left...
5.	Leiomyoma (Uterine Fibroids) 01/01/2005 - "In light of therapeutic efficacy and few adverse effects, SERM and SPRM may hold promise as novel treatment modalities for leiomyoma" 07/01/2000 - "Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma." 12/01/2001 - "This antagonist activity in the uterine myometrium suggests that SERMs may be useful in the treatment of uterine leiomyoma." 01/01/2007 - "Further studies are required to establish evidence of benefit of SERMs in treating women with uterine fibroids." 01/01/2007 - "AUTHORS' CONCLUSIONS: There is no evidence from the limited number of studies that SERMs reduce the size of fibroids or improve clinical outcomes" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Selective Estrogen Receptor Modulators (SERM)
2.	Tamoxifen
3.	Raloxifene (Evista)
4.	Estrogens (Estrogen)
5.	Hormones
6.	Aromatase Inhibitors
7.	Estradiol (Estrace)
8.	Diphosphonates
9.	tartrate salt cis- 1R- (4'- pyrrolidinoethoxyphenyl)- 2S- phenyl- 6- hydroxy- 1,2,3,4- tetrahydronaphthalene (Lasofoxifene)
10.	pyrrolidino-4-iodotamoxifen (idoxifene)

Related Therapies and Procedures

1.	Chemoprevention
2.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
3.	Drug Therapy (Chemotherapy)
4.	Estrogen Replacement Therapy
5.	Heterologous Transplantation (Xenotransplantation)

Best Treatments:
Research Summary Report
on Breast Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 3579 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>